Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 444200

Next Previous
X
Search
Drug Profile

SAR 444200

Alternative Names: SAR-444200

Latest Information Update: 15 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 31 May 2024 Adverse events, pharmacokinetics and pharmacodynamics data from phase-I/II trial in Solid tumours (onotherapy) presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 20 Oct 2023 Adverse events and pharmacodynamics data from a phase I/II trial in Solid tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 20 Sep 2022 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater, Inoperable/Unresectable) in China (IV) (NCT05450562)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top